Total trials
310
Active
36
Phase 3
8
Total enrollment
1,108,903
Pipeline matrix
Showing 7 of 7 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexamethasone | — | — | — | — | — | 2 | |
| Methylprednisolone | — | — | — | — | 2 | ||
| 2% Lidocaine HCl | — | — | — | — | — | 1 | |
| Zinc Picolinate 15 Mg | — | — | — | — | — | 1 | |
| MDMA Assisted Therapy | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | 2 | ||
| Tirzepatide | — | — | — | — | — | 1 |
Next readouts
- 2026-08
- 2027-01-01
- 2027-04
- 2027-05-01
- 2027-07
Top conditions
- Cancer14
- Obesity10
- Lung Diseases8
- Chronic Pain7
- Contraception7
- Depression6
- Hypertension5
- Diabetes Mellitus5
Frequently asked questions about University of New Mexico
- How many clinical trials does University of New Mexico have on ClinicalTrials.gov?
- University of New Mexico is listed as the lead sponsor on 310 clinical trials in ClinicalTrials.gov, 36 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of New Mexico's trials are in Phase 3?
- 8 of University of New Mexico's trials are in Phase 3, spread across 7 active drug programs.
- What therapeutic areas does University of New Mexico focus on?
- University of New Mexico's most-studied conditions on ClinicalTrials.gov are Cancer, Obesity, Lung Diseases, Chronic Pain, Contraception.
- When are University of New Mexico's next clinical trial readouts?
- University of New Mexico has 5 upcoming primary-completion readouts tracked here; the soonest is “Effect of Tirzepatide on Markers of MASLD in Patients With Obesity”, expected around 2026-08.